- Home
- RMCO vs ECOR Comparison
RMCO vs ECOR Comparison
Compare RMCO & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCO | ECOR |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.7M | 52.4M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | RMCO | ECOR |
|---|---|---|
| Price | $3.97 | $6.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 23.6K | ★ 52.0K |
| Earning Date | 01-01-0001 | 04-11-2026 |
| Dividend Yield | ★ 0.25% | N/A |
| EPS Growth | N/A | ★ 53.51 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,182,000.00 |
| Revenue This Year | $531.90 | $28.92 |
| Revenue Next Year | $200.00 | $32.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 57.09 |
| 52 Week Low | $0.92 | $4.16 |
| 52 Week High | $5.00 | $18.41 |
Technical Indicators
Market Signals| Indicator | RMCO | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 51.58 | 50.87 |
| Support Level | $3.81 | $5.15 |
| Resistance Level | $4.12 | $6.89 |
| Average True Range (ATR) | 0.23 | 0.54 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 46.59 | 47.06 |
Price Performance
Historical ComparisonAbout RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.